# Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?

> **NCT03232112** · PHASE2 · COMPLETED · sponsor: **Anders Fink-Jensen, MD, DMSci** · enrollment: 152 (actual)

## Conditions studied

- Alcohol Dependence, in Remission
- Addiction, Alcohol

## Interventions

- **DRUG:** Exenatide 2 MG Injection
- **DRUG:** BD PosiFlush (saline)

## Key facts

- **NCT ID:** NCT03232112
- **Lead sponsor:** Anders Fink-Jensen, MD, DMSci
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2017-08-07
- **Primary completion:** 2020-03-15
- **Final completion:** 2020-10-05
- **Target enrollment:** 152 (ACTUAL)
- **Last updated:** 2021-06-04

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03232112

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03232112, "Does Treatment With GLP-1 Reduce Alcohol Intake in Patients With Alcohol Dependence?". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT03232112. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*